Orion Corporation
Phase1 is Orion’s paid trainee programme designed for university students, bringing together a large and diverse group of talents from various fields every year. In addition to interesting summer jobs with meaningful projects, the programme offers a variety of events, networking opportunities with other Phase1 Trainees and Orion employees, as well as small group mentoring to support your career! Could this be the first research phase of your Orion career? You can find more information about the Phase1 trainee programme on Orion’s website .
Are you eager to learn and contribute to the development of safer and more effective medicines? We are looking for a motivated Phase 1 Trainee to join our ADMET & MetID team and gain hands‑on experience in drug discovery. As an ADMET & MetID Trainee, you will:
Assist in developing predictive assays to evaluate drug safety and efficacy.
Support screening and analysis of ADME properties (Absorption, Distribution, Metabolism, and Excretion) for potential new drug candidates.
Work closely with experienced scientists and learn cutting‑edge techniques in pharmaceutical research.
Contribute to ongoing projects that make a real impact on patient health
This on‑site position is temporary, 1 May - 31 August 2026, and it is based in Turku, Finland.
Your key responsibilities
Support the development of screening assays for permeability and specific transporter interactions.
Screen test molecules and characterize their in‑vitro ADME properties.
Process, interpret, and report data to internal stakeholders, including ADME scientists, medicinal chemists, and project team members
What we offer
A unique opportunity to gain practical experience in a leading research environment.
Mentorship from experts in ADME and drug development.
A collaborative and innovative workplace where your ideas matter
At Orion, your work creates true impact and well‑being for our customers, patients and society at large. Our culture of friendliness, respect, mutual appreciation and diversity creates a safe working environment where you can strive for excellence. We offer a wealth of career paths and development opportunities that support the development of innovative solutions and improving the quality of life.
MSc, or equivalent studies, in a relevant field such as cell biology, pharmacy, or biochemistry.
Hands‑on experience with in‑vitro laboratory work, preferably with cell‑based systems.
Practical and theoretical understanding of DMPK (Drug Metabolism and Pharmacokinetics).
Experience working with in‑vitro ADME assays.
Ability to develop methods and troubleshoot effectively.
Curiosity, attention to detail, and a strong willingness to learn.
Excellent communication skills in English
Additional advantage: Hands‑on experience with LC‑MS/MS instruments and quantitative analytics.
How to apply and additional information Please apply as soon as possible, but no later than February 1st 2026. We might start interviewing candidates during the application time, so please ensure that we have your application as soon as possible!
For more details on the position, please contact Satu‑Maarit Heinonen (Head of ADMET & MetID) tel. +358 50 966 2060. Available for calls on 12 January (12:00‑14:00 EET) and 15 January (9:00‑11:00 EET).
Our Phase1 trainees will be paid a monthly salary of €2370–2625, depending on the number of completed study credits. In addition, the Phase1 trainees are eligible to various employee benefits offered by the company.
If you would like to know more about the application process and timelines, please visit our website . Welcome to build well‑being with us next summer 2026!
Approved medical examination which also includes drug testing is required prior to the employment. We will also carry out a security clearance prior to the employment for the selected person.
Orion’s pharmaceutical innovations are created within its R&D organization. We employ around 400 top professionals in the field of drug discovery and development. We work globally: in Espoo and Turku in Finland, in Nottingham in England and in New York, NY, USA. Orion R&D and the Innovative Medicines business division are dedicated to making a transformation to become a global player in the pain and oncology therapy areas.
The ADMET & MetID unit, part of Integrated DMPK and Safety at Orion R&D, is responsible for early ADME and safety assessments of new drug candidates. We provide assay services and scientific expertise in in‑vitro ADME, toxicology, and metabolite identification (MetID) for small molecule projects throughout the drug development process, supporting our key therapy areas: Oncology and Pain.
You will join a multidisciplinary team of expert in‑vitro scientists and experienced research associates working across two locations: Espoo and Turku.
#LI-DNI
About Us Orion Pharma is a globally operating Nordic pharmaceutical company – a builder of well‑being for over a hundred years.
We’re home to more than 4,000 Orionees around the world, and we’re proud to be known as a responsible employer and a great place to work. At Orion Pharma, people are truly valued and trusted, encouraged to grow, and supported by a culture where every voice is heard. We appreciate each other, strive for excellence, and build the future.
Together we develop, manufacture, and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Our extensive portfolio includes proprietary and generic medicines as well as consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion Pharma are used to treat cancer, neurological diseases, respiratory diseases, and more.
We offer careers with a clear purpose: empowering people to live their lives to the fullest.
#J-18808-Ljbffr
Are you eager to learn and contribute to the development of safer and more effective medicines? We are looking for a motivated Phase 1 Trainee to join our ADMET & MetID team and gain hands‑on experience in drug discovery. As an ADMET & MetID Trainee, you will:
Assist in developing predictive assays to evaluate drug safety and efficacy.
Support screening and analysis of ADME properties (Absorption, Distribution, Metabolism, and Excretion) for potential new drug candidates.
Work closely with experienced scientists and learn cutting‑edge techniques in pharmaceutical research.
Contribute to ongoing projects that make a real impact on patient health
This on‑site position is temporary, 1 May - 31 August 2026, and it is based in Turku, Finland.
Your key responsibilities
Support the development of screening assays for permeability and specific transporter interactions.
Screen test molecules and characterize their in‑vitro ADME properties.
Process, interpret, and report data to internal stakeholders, including ADME scientists, medicinal chemists, and project team members
What we offer
A unique opportunity to gain practical experience in a leading research environment.
Mentorship from experts in ADME and drug development.
A collaborative and innovative workplace where your ideas matter
At Orion, your work creates true impact and well‑being for our customers, patients and society at large. Our culture of friendliness, respect, mutual appreciation and diversity creates a safe working environment where you can strive for excellence. We offer a wealth of career paths and development opportunities that support the development of innovative solutions and improving the quality of life.
MSc, or equivalent studies, in a relevant field such as cell biology, pharmacy, or biochemistry.
Hands‑on experience with in‑vitro laboratory work, preferably with cell‑based systems.
Practical and theoretical understanding of DMPK (Drug Metabolism and Pharmacokinetics).
Experience working with in‑vitro ADME assays.
Ability to develop methods and troubleshoot effectively.
Curiosity, attention to detail, and a strong willingness to learn.
Excellent communication skills in English
Additional advantage: Hands‑on experience with LC‑MS/MS instruments and quantitative analytics.
How to apply and additional information Please apply as soon as possible, but no later than February 1st 2026. We might start interviewing candidates during the application time, so please ensure that we have your application as soon as possible!
For more details on the position, please contact Satu‑Maarit Heinonen (Head of ADMET & MetID) tel. +358 50 966 2060. Available for calls on 12 January (12:00‑14:00 EET) and 15 January (9:00‑11:00 EET).
Our Phase1 trainees will be paid a monthly salary of €2370–2625, depending on the number of completed study credits. In addition, the Phase1 trainees are eligible to various employee benefits offered by the company.
If you would like to know more about the application process and timelines, please visit our website . Welcome to build well‑being with us next summer 2026!
Approved medical examination which also includes drug testing is required prior to the employment. We will also carry out a security clearance prior to the employment for the selected person.
Orion’s pharmaceutical innovations are created within its R&D organization. We employ around 400 top professionals in the field of drug discovery and development. We work globally: in Espoo and Turku in Finland, in Nottingham in England and in New York, NY, USA. Orion R&D and the Innovative Medicines business division are dedicated to making a transformation to become a global player in the pain and oncology therapy areas.
The ADMET & MetID unit, part of Integrated DMPK and Safety at Orion R&D, is responsible for early ADME and safety assessments of new drug candidates. We provide assay services and scientific expertise in in‑vitro ADME, toxicology, and metabolite identification (MetID) for small molecule projects throughout the drug development process, supporting our key therapy areas: Oncology and Pain.
You will join a multidisciplinary team of expert in‑vitro scientists and experienced research associates working across two locations: Espoo and Turku.
#LI-DNI
About Us Orion Pharma is a globally operating Nordic pharmaceutical company – a builder of well‑being for over a hundred years.
We’re home to more than 4,000 Orionees around the world, and we’re proud to be known as a responsible employer and a great place to work. At Orion Pharma, people are truly valued and trusted, encouraged to grow, and supported by a culture where every voice is heard. We appreciate each other, strive for excellence, and build the future.
Together we develop, manufacture, and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Our extensive portfolio includes proprietary and generic medicines as well as consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion Pharma are used to treat cancer, neurological diseases, respiratory diseases, and more.
We offer careers with a clear purpose: empowering people to live their lives to the fullest.
#J-18808-Ljbffr